Pfizer announces positive results from phase 3 JADE REGIMEN study in patients with moderate to severe atopic dermatitis

After achieving clinical response in 12 week induction period of trial (n=1233), patients continuing on 200mg or switched to lower dose (100mg) had significantly higher probability of not experiencing flare vs. placebo through week 52 (81.1%, 57.4%, and 19.1%, respectively).

SPS commentary:

In October, the FDA granted Priority Review and the European Medicines Agency accepted regulatory submission for abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, as treatment of moderate to severe atopic dermatitis.

Biospace Inc.